Genomics plc, a UK-based precision healthcare technology developer backed by drug manufacturer Vertex Pharmaceuticals, closed a $30m funding round on Monday.

F-Prime Capital, an investment affiliate of financial services and investment group Fidelity, provided the funding together with university venture fund Oxford Sciences Innovation (OSI), Foresite Capital and Lansdowne Partners.

Founded in 2014, Genomics has developed a machine learning-powered genomic analytics platform that determines the risk of individuals for common diseases before they manifest.

Apart from delivering its population health management services and clinical decision support tools, the company also uses its insights to support the discovery and development of treatments. It will use the equity financing to expand its platform.

Genomics closed a $41.7m series B round in 2018 backed by Vertex Pharmaceuticals, OSI, commercialisation firm IP Group, F-Prime Capital, Foresite Capital, Landsdowne Partners, Invesco Perpetual, Tanarra and the now-defunct Woodford Investment Management.

University of Oxford had contributed to the company’s $16.2m series A round in 2014 together with IP Group and its IP Venture Fund II, as well as Invesco Perpetual, Lansdowne Partners, Woodford Investment Management and Wylie Family Trust.

The original version of this article appeared on our sister site, Global University Venturing.

Genomics, a UK-based precision healthcare spinout of University of Oxford, closed a $30m funding round yesterday backed by university venture fund Oxford Sciences Innovation (OSI).
Foresite Capital and F-Prime Capital, an investment affiliate of financial services group Fidelity, and Lansdowne Partners also participated in the round.
Founded in 2014, Genomics has developed a machine learning-powered genomic analytics platform that determines the risk of individuals for common diseases before they manifest.
Apart from delivering its population health management services and clinical decision support tools, the company also uses its insights to support the discovery and development of treatments. It will use the equity financing to expand its platform.
Prof Sir Peter Donnelly, co-founder and CEO of Genomics, said: “This new approach to healthcare, called Genomic Prevention, can identify people at risk for developing each disease early, and is critical to driving more efficient screening and a prevention first approach to healthcare.
“More successful disease prevention will improve patient lives and make healthcare systems more sustainable.”
Genomics raised $42m in a series B round in 2018 backed by OSI, commercialisation firm IP Group, drug manufacturer Vertex Pharmaceuticals, F-Prime Capital and Foresite Capital.
Landsdowne Partners, Invesco Perpetual and Tanarra also contributed to the series B round, as did the now-defunct Woodford Investment Management.
University of Oxford contributed to a $16.2m series A round in 2014 together with IP Group and its IP Venture Fund II, Invesco Perpetual, Lansdowne, Woodford and Wylie Family Trust.